# A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients

> **NCT00282243** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 70 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** tacrolimus modified release (MR)
- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT00282243
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282243, "A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00282243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*